Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Atreca Inc | BCEL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.15 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.15 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.1023 - 1.2642 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.15 | USD |
Atreca Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 5.94M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Atreca News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BCEL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.289 | 0.34 | 0.15 | 0.2561996 | 760,832 | -0.139 | -48.10% |
| 6 Months | 0.2362 | 0.4448 | 0.1023 | 0.2676482 | 5,615,013 | -0.0862 | -36.49% |
| 1 Year | 0.91 | 1.2642 | 0.1023 | 0.2923133 | 2,999,995 | -0.76 | -83.52% |
| 3 Years | 12.06 | 12.73 | 0.1023 | 1.60 | 1,316,011 | -11.91 | -98.76% |
| 5 Years | 19.90 | 29.35 | 0.1023 | 2.87 | 878,886 | -19.75 | -99.25% |
Atreca Description
| Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture IRC technology Atreca has an unparalleled insight into how cancer patients immune responses can drive better clinical outcomes. Atreca was founded by scientists industry experts and investors who share the vision that unlocking the immune response of todays patients is the key to creating a new generation of therapies. Atreca is looking for talented entrepreneurial people who are dedicated to making a positive impact on human health. |
